Débora S. Bruno

5.3k total citations
45 papers, 352 citations indexed

About

Débora S. Bruno is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Débora S. Bruno has authored 45 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Débora S. Bruno's work include Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Débora S. Bruno is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Débora S. Bruno collaborates with scholars based in United States, Canada and Japan. Débora S. Bruno's co-authors include Nathan A. Berger, Lisa M. Hess, Xiaohong Li, Eric Wen Su, Yajun Emily Zhu, Jay H. Herman, Cheng Zhou, Yael Klionsky, Alexander I. Spira and Valentina Boni and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Débora S. Bruno

37 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Débora S. Bruno United States 12 215 128 82 77 51 45 352
Jia-Wei Lv China 7 138 0.6× 95 0.7× 71 0.9× 60 0.8× 63 1.2× 8 268
Vishal Navani Canada 11 205 1.0× 172 1.3× 49 0.6× 42 0.5× 87 1.7× 38 338
Shiven B. Patel United States 12 276 1.3× 168 1.3× 41 0.5× 61 0.8× 106 2.1× 47 420
Melinda Laine Hsu United States 11 214 1.0× 119 0.9× 44 0.5× 111 1.4× 160 3.1× 28 422
Laura Iezzi Italy 11 308 1.4× 79 0.6× 102 1.2× 84 1.1× 76 1.5× 21 411
Karl Verpoort Germany 7 222 1.0× 53 0.4× 98 1.2× 123 1.6× 64 1.3× 10 370
Berta Hernández Spain 10 243 1.1× 77 0.6× 32 0.4× 114 1.5× 43 0.8× 17 352
Valérie Cristina Switzerland 7 175 0.8× 101 0.8× 35 0.4× 34 0.4× 70 1.4× 15 364
Hakaru Tadokoro Brazil 10 369 1.7× 237 1.9× 76 0.9× 109 1.4× 83 1.6× 33 514
Maria-Pilar Barretina-Ginesta Spain 10 243 1.1× 65 0.5× 63 0.8× 64 0.8× 68 1.3× 35 511

Countries citing papers authored by Débora S. Bruno

Since Specialization
Citations

This map shows the geographic impact of Débora S. Bruno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Débora S. Bruno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Débora S. Bruno more than expected).

Fields of papers citing papers by Débora S. Bruno

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Débora S. Bruno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Débora S. Bruno. The network helps show where Débora S. Bruno may publish in the future.

Co-authorship network of co-authors of Débora S. Bruno

This figure shows the co-authorship network connecting the top 25 collaborators of Débora S. Bruno. A scholar is included among the top collaborators of Débora S. Bruno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Débora S. Bruno. Débora S. Bruno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hirunpattarasilp, Chanawee, Pingfu Fu, Seunghee Margevicius, et al.. (2025). Outcomes in patients with multiple sclerosis and solid organ cancers treated with immune checkpoint inhibitors. Neuro-Oncology Advances. 7(1). vdaf048–vdaf048.
2.
Mambetsariev, Isa, Siddhika Pareek, Leonidas Arvanitis, et al.. (2025). Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition. Current Oncology. 32(10). 554–554.
3.
Rugo, Hope S., Aditya Bardia, Débora S. Bruno, et al.. (2025). US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Supportive Care in Cancer. 33(9). 756–756. 1 indexed citations
4.
Vaishampayan, Ulka N., Jameel Muzaffar, Ira Winer, et al.. (2024). Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). Journal for ImmunoTherapy of Cancer. 12(11). e010143–e010143. 14 indexed citations
5.
6.
Bruno, Débora S., et al.. (2024). Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 25(19). 10861–10861. 2 indexed citations
7.
Bruno, Débora S., Xiaohong Li, & Lisa M. Hess. (2024). Biomarker Testing, Targeted Therapy and Clinical Trial Participation by Race Among Patients With Lung Cancer: A Real-World Medicaid Database Study. JTO Clinical and Research Reports. 5(3). 100643–100643. 2 indexed citations
8.
9.
Bruno, Débora S., Yilun Sun, Shearwood McClelland, et al.. (2024). Impact of Clinical Trial Design on Recruitment of Racial and Ethnic Minorities. Journal of Cancer Education. 39(5). 567–572.
10.
Parker, Ben, et al.. (2024). Predictive risk score for isolated brain metastasis in non-small cell lung cancer. Journal of Thoracic Disease. 16(6). 3794–3804. 1 indexed citations
11.
Jiang, Changchuan, Chi Wen, Hui Xie, et al.. (2023). Subjective and Objective Hearing Loss Among US Adult Cancer Survivors. JAMA Otolaryngology–Head & Neck Surgery. 149(12). 1101–1101.
12.
He, Kai, David Berz, Shirish M. Gadgeel, et al.. (2023). MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology. 18(7). 907–921. 20 indexed citations
13.
14.
Bebek, Gürkan, et al.. (2023). Microbiome, socioeconomic status (SES), fiber intake, and response to checkpoint inhibitor therapy in patients with non-small cell lung cancer (NSCLC): A pilot study.. Journal of Clinical Oncology. 41(16_suppl). e14710–e14710. 1 indexed citations
15.
16.
Stabellini, Nickolas, Débora S. Bruno, Lifen Cao, et al.. (2022). Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice. JTO Clinical and Research Reports. 3(4). 100307–100307. 29 indexed citations
17.
18.
Bruno, Débora S. & Nathan A. Berger. (2020). Impact of bariatric surgery on cancer risk reduction. Annals of Translational Medicine. 8(S1). S13–S13. 34 indexed citations
19.
Zhou, Cheng, et al.. (2019). Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection. Case Reports in Oncology. 12(1). 164–170. 17 indexed citations
20.
Almeida, Francisco A., et al.. (2011). Hemothorax Treated With Indwelling Tunneled Pleural Catheter. Journal of Bronchology & Interventional Pulmonology. 18(3). 261–264. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jia-Wei Lv Breakdown of academic impact, for papers by Vishal Navani Breakdown of academic impact, for papers by Shiven B. Patel Breakdown of academic impact, for papers by Melinda Laine Hsu Breakdown of academic impact, for papers by Laura Iezzi Breakdown of academic impact, for papers by Karl Verpoort Breakdown of academic impact, for papers by Berta Hernández Breakdown of academic impact, for papers by Valérie Cristina Breakdown of academic impact, for papers by Hakaru Tadokoro Breakdown of academic impact, for papers by Maria-Pilar Barretina-Ginesta
Rankless by CCL
2026